COPN Stock Overview
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide.
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF47.50|
|52 Week High||CHF76.50|
|52 Week Low||CHF42.30|
|1 Month Change||-8.48%|
|3 Month Change||-2.16%|
|1 Year Change||-34.57%|
|3 Year Change||-39.41%|
|5 Year Change||-68.33%|
|Change since IPO||113.00%|
Recent News & Updates
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...
|COPN||CH Pharmaceuticals||CH Market|
Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned -0.7% over the past year.
Return vs Market: COPN underperformed the Swiss Market which returned -15% over the past year.
|COPN Average Weekly Movement||4.1%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||4.4%|
|10% most volatile stocks in CH Market||7.6%|
|10% least volatile stocks in CH Market||2.2%|
Stable Share Price: COPN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: COPN's weekly volatility (4%) has been stable over the past year.
About the Company
|1997||292||Alessandro Della Cha||https://www.cosmopharma.com|
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler’s diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
|COPN fundamental statistics|
Is COPN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COPN income statement (TTM)|
|Cost of Revenue||€36.40m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.15|
|Net Profit Margin||45.14%|
How did COPN perform over the long term?See historical performance and comparison